Efficacy and safety of enzalutamide in patients with metastatic hormone-sensitive prostate cancer (mHSPC) and cardiometabolic comorbidities and/or related concomitant medications: ARCHES post hoc

Arnulf Stenzl, MD

May 31, 2026; 9:00 AM CDT